Loading
Use an ultra-sensitive blood test after two cycles to decide who needs more than R-CHOP and who can stop early.
The idea is to use an ultra-sensitive ctDNA assay such as PhasED-seq after two cycles of R-CHOP in frontline diffuse large B-cell lymphoma to decide who needs escalation and who can stop early. Interim PET has poor positive predictive value, whereas ctDNA clearance after cycle 2 or at end of treatment predicts cure better, and ctDNA kinetics track outcome across cohorts. The hypothesis is that patients with undetectable ctDNA after two cycles do as well with four cycles as six, while those with detectable ctDNA benefit from switching to a bispecific-containing regimen such as epcoritamab-R-CHOP. The test is a randomised response-adapted trial with ctDNA-defined arms, non-inferior for de-escalation and superior for escalation on event-free survival.
One of the most cited trial reports Europe PMC returns for Epcoritamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for Epcoritamab in Diffuse large B-cell lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One technology page and one idea page on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Shares EPCORE DLBCL-1, EPCORE NHL-1, Epcoritamab, Diffuse large B-cell lymphoma.
Shares A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China, EPCORE DLBCL-2, EPCORE DLBCL-1, A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita.
Shares EPCORE DLBCL-1, EPCORE NHL-1, Epcoritamab, Diffuse large B-cell lymphoma.
Shares Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial, Diffuse large B-cell lymphoma.
Shares EPCORE DLBCL-1, EPCORE NHL-1, Diffuse large B-cell lymphoma.
Shares ctDNA monitoring in lymphoma (PhasED-seq, clonoSEQ), Minimal / molecular residual disease (MRD), Diffuse large B-cell lymphoma.
Shares Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, Minimal / molecular residual disease (MRD), Diffuse large B-cell lymphoma.
Shares Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, Minimal / molecular residual disease (MRD), Diffuse large B-cell lymphoma.